Literature DB >> 18167354

RNA-binding protein TLS is a major nuclear aggregate-interacting protein in huntingtin exon 1 with expanded polyglutamine-expressing cells.

Hiroshi Doi1, Kazumasa Okamura, Peter O Bauer, Yoshiaki Furukawa, Hideaki Shimizu, Masaru Kurosawa, Yoko Machida, Haruko Miyazaki, Kenichi Mitsui, Yoshiyuki Kuroiwa, Nobuyuki Nukina.   

Abstract

Formation of intracellular aggregates is the hallmark of polyglutamine (polyQ) diseases. We analyzed the components of purified nuclear polyQ aggregates by mass spectrometry. As a result, we found that the RNA-binding protein translocated in liposarcoma (TLS) was one of the major components of nuclear polyQ aggregate-interacting proteins in a Huntington disease cell model and was also associated with neuronal intranuclear inclusions of R6/2 mice. In vitro study revealed that TLS could directly bind to truncated N-terminal huntingtin (tNhtt) aggregates but could not bind to monomer GST-tNhtt with 18, 42, or 62Q, indicating that the tNhtt protein acquired the ability to sequester TLS after forming aggregates. Thioflavin T assay and electron microscopic study further supported the idea that TLS bound to tNhtt-42Q aggregates at the early stage of tNhtt-42Q amyloid formation. Immunohistochemistry showed that TLS was associated with neuronal intranuclear inclusions of Huntington disease human brain. Because TLS has a variety of functional roles, the sequestration of TLS to polyQ aggregates may play a role in diverse pathological changes in the brains of patients with polyQ diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18167354     DOI: 10.1074/jbc.M705306200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  51 in total

1.  Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease.

Authors:  Manuela Neumann; Sigrun Roeber; Hans A Kretzschmar; Rosa Rademakers; Matt Baker; Ian R A Mackenzie
Journal:  Acta Neuropathol       Date:  2009-08-09       Impact factor: 17.088

Review 2.  Biomarker studies in multiple sclerosis: from proteins to noncoding RNAs.

Authors:  Xiao-Fang Liu; Yue-Bei Luo; Zhao-Hui Luo; Huan Yang
Journal:  Neurochem Res       Date:  2014-07-29       Impact factor: 3.996

3.  Deciphering genetic interactions between ALS genes using C. elegans.

Authors:  Martine Therrien; J Alex Parker
Journal:  Worm       Date:  2014-05-08

Review 4.  The role of FUS gene variants in neurodegenerative diseases.

Authors:  Hao Deng; Kai Gao; Joseph Jankovic
Journal:  Nat Rev Neurol       Date:  2014-05-20       Impact factor: 42.937

Review 5.  Long non-coding RNAs in nervous system function and disease.

Authors:  Irfan A Qureshi; John S Mattick; Mark F Mehler
Journal:  Brain Res       Date:  2010-04-07       Impact factor: 3.252

Review 6.  Fused in Sarcoma Neuropathology in Neurodegenerative Disease.

Authors:  Ian R A Mackenzie; Manuela Neumann
Journal:  Cold Spring Harb Perspect Med       Date:  2017-12-01       Impact factor: 6.915

7.  An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors.

Authors:  Rodrigo A Fuentealba; Jayne Marasa; Marc I Diamond; David Piwnica-Worms; Conrad C Weihl
Journal:  Hum Mol Genet       Date:  2011-11-03       Impact factor: 6.150

8.  The seeds of neurodegeneration: prion-like spreading in ALS.

Authors:  Magdalini Polymenidou; Don W Cleveland
Journal:  Cell       Date:  2011-10-28       Impact factor: 41.582

9.  Intranuclear aggregation of mutant FUS/TLS as a molecular pathomechanism of amyotrophic lateral sclerosis.

Authors:  Takao Nomura; Shoji Watanabe; Kumi Kaneko; Koji Yamanaka; Nobuyuki Nukina; Yoshiaki Furukawa
Journal:  J Biol Chem       Date:  2013-11-26       Impact factor: 5.157

Review 10.  Applications of high content screening in life science research.

Authors:  Joseph M Zock
Journal:  Comb Chem High Throughput Screen       Date:  2009-11       Impact factor: 1.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.